Obesity drugs clinical pipeline U.S. 2018, by type and phase

Published by
Matej Mikulic,
Apr 18, 2019
This statistic depicts the number of the clinical pipeline for novel obesity drugs based on number of drug programs as of September 2018, by type and phase. According to the data, there were 12 phase I chemical trials for novel chemicals with new MOAs.

Clinical pipeline for obesity drugs in the U.S. as of 2018, by type and phase

© Statista 2023
Download
Show detailed source information?
Register for free
Already a member?
Log in
Sources

Use Ask Statista Research Service

Release date

2019

Region

United States

Survey time period

as of September 2018

Supplementary notes

NDA/BLA = new drug application/biologic license application
NME = new molecular entity

Citation formats
Statista Accounts: Access All Statistics. Starting from $1,788 USD / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account.

Starter Account
The ideal entry-level account for individual users
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$149 USD / Month *
Professional Account
Full access

Business Solutions including all features.

* Prices do not include sales tax.

Other statistics that may interest you

The most important statistics
The most important statistics
The most important statistics
The most important statistics
The most important statistics

Other statistics that may interest you Statistics on

About the industry

10

About the region

10

Selected statistics

6

Other regions

10

Related statistics

10

Further related statistics

10

Further Content: You might find this interesting as well

Statistics

Topics

Diabetes in CanadaDeath in CanadaObesity in CanadaDiabetesDiabetes in the U.S.
Statista Accounts: Access All Statistics. Starting from $1,788 USD / Year
Learn more about how Statista can support your business.
Menu